Corona Remedies’ Rs 655.37-crore IPO has seen strong demand, with overall subscription at 9.33 times by Day 2. The GMP of around Rs 270 suggests a potential listing near Rs 1,332. While the company shows robust growth, brand concentration, regional dependence, and supply-chain risks remain. Analysts, however, maintain a long-term “subscribe” view given its strong fundamentals and strategic positioning.
Source :- Markets-Economic Times Read More
